- LAVA Therapeutics N.V. and XOMA Royalty Corporation have amended their definitive share purchase agreement, with the cash amount per share for tendering shareholders now set at **$1.04**, a reduction from the originally agreed range of $1.16 to $1.24.  **[1840748_0001104659-25-100317_tm2528774d1_ex99-1.htm:0]** **[1840748_0001104659-25-100317_tm2528774d1_8k.htm:1]** 
- The amendment introduces a new right for Contingent Value Right (CVR) holders to receive up to approximately **$0.23 per CVR**, dependent on the final determination of certain potential liabilities.  **[1840748_0001104659-25-100317_tm2528774d1_ex99-1.htm:0]** 
- The minimum net-cash closing condition for the acquisition has been lowered to **$24.5 million** from the previous **$31.5 million**.  **[1840748_0001104659-25-100317_tm2528774d1_ex99-1.htm:0]** **[1840748_0001104659-25-100317_tm2528774d1_8k.htm:2]** 
- The tender offer, which was previously scheduled to expire on October 17, 2025, has been extended until **November 12, 2025**, and the Extraordinary General Meeting of Shareholders is reconvened for **November 7, 2025**.  **[1840748_0001104659-25-100317_tm2528774d1_ex99-1.htm:0]** **[1840748_0001104659-25-100317_tm2528774d1_8k.htm:3]**

LAVA Therapeutics (LVTX)